Boston Scientific Corporation Stock

Equities

BSX

US1011371077

Advanced Medical Equipment & Technology

Market Closed - Nyse 16:00:02 2024-06-18 EDT 5-day change 1st Jan Change
76.31 USD +0.16% Intraday chart for Boston Scientific Corporation -1.42% +32.00%
Sales 2024 * 16B 21.92B Sales 2025 * 17.59B 24.11B Capitalization 112B 154B
Net income 2024 * 2.2B 3.02B Net income 2025 * 2.74B 3.75B EV / Sales 2024 * 7.42 x
Net Debt 2024 * 6.42B 8.8B Net Debt 2025 * 3.62B 4.97B EV / Sales 2025 * 6.58 x
P/E ratio 2024 *
51.9 x
P/E ratio 2025 *
42.1 x
Employees 48,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.16%
1 week-1.42%
Current month+0.98%
1 month+2.22%
3 months+12.57%
6 months+36.71%
Current year+32.00%
More quotes
1 week
75.38
Extreme 75.38
77.03
1 month
74.29
Extreme 74.29
77.64
Current year
57.11
Extreme 57.11
77.64
1 year
48.35
Extreme 48.35
77.64
3 years
34.98
Extreme 34.98
77.64
5 years
24.10
Extreme 24.1
77.64
10 years
11.10
Extreme 11.1
77.64
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 11-10-16
Director of Finance/CFO 58 96-11-30
Chief Tech/Sci/R&D Officer - 09-08-31
Members of the board TitleAgeSince
Director/Board Member 71 16-07-12
Director/Board Member 61 21-06-22
Director/Board Member 69 15-03-31
More insiders
Date Price Change Volume
24-06-18 76.31 +0.16% 5,365,864
24-06-17 76.19 -0.74% 6,443,574
24-06-14 76.76 -0.26% 3,540,282
24-06-13 76.96 -0.58% 4,054,303
24-06-12 77.41 +0.34% 3,219,862

Delayed Quote Nyse, June 18, 2024 at 04:00 pm

More quotes
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows: - cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%); - endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ; - neuromodulation (2%). The United States account for 59.2% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
76.31 USD
Average target price
82 USD
Spread / Average Target
+7.45%
Consensus